Aileron Therapeutics

86 articles with Aileron Therapeutics

• Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924

  8/3/2020

  Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported positive interim data from dose optimization part of study demonstrated 0.3 mg/kg dose of ALRN-6924, now being evaluated in expansion cohort, resulted in most robust chemoprotective effects

• 

  Clinical Catch-Up: June 29-July 3

  7/6/2020

  Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
• 

  Clinical Catch-Up: October 14-18

  10/21/2019

  Last week was busy for clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: September 23-27

  9/30/2019

  It was a moderately busy week for clinical trial news. Here’s a look.
• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.
• 

  Is There a Biotech Bubble Brewing in Boston?

  3/21/2018

  Billions of dollars are being invested in Boston-based life science companies.
• 

  The 2017 Biotech IPO Winners and Losers

  12/21/2017

  Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.

• Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

  12/12/2017

  The data were reviewed in separate oral presentations by researchers from the Dana-Farber Cancer Institute and the Albert Einstein College of Medicine during the 2017 American Society of Hematology Annual Meeting.

• Aileron Therapeutics Reports Third Quarter 2017 Financial Results

  11/10/2017

  Cash, cash equivalents and investments as of September 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016.

• Aileron Therapeutics Added To The Russell 2000, Russell 3000 And Russell Microcap Indexes

  9/19/2017

• Aileron Therapeutics Announces Presentation Of Preclinical Data With ALRN-6924 At The International Society Of Experimental Hematology Annual Scientific Meeting

  8/24/2017

• Aileron Therapeutics Reports Second Quarter 2017 Financial Results

  8/11/2017

• Aileron Therapeutics Announces Pricing Of Initial Public Offering

  6/29/2017

• Aileron Therapeutics Appoints Donald Dougherty As Senior Vice President And Chief Financial Officer

  6/15/2017

• Aileron Therapeutics Files For $69 Million IPO As New Offerings Heat Up

  6/6/2017

• Aileron Therapeutics Release: Anti-Tumor Activity Observed In Phase I Trial Of Novel P53-Targeting Drug ALRN-6924

  6/5/2017

• Aileron Therapeutics Announces Oral Presentation At ASCO On ALRN-6924 Targeting p53

  5/18/2017

• Aileron Therapeutics Initiates Phase 1 Cancer Study Of ALRN-6924 In Advanced Hematologic And Solid Malignancies With Wild Type P53

  2/12/2015

• Aileron Therapeutics Appoints Evan Lippman As Chief Financial And Business Officer

  1/8/2015